P2Y\textsubscript{2} receptor agonists for the treatment of dry eye disease: a review

Oliver C F Lau\textsuperscript{1}
Chameen Samarawickrama\textsuperscript{1,2}
Simon E Skalicky\textsuperscript{1,3}

\textsuperscript{1}Sydney Eye Hospital, Sydney, NSW, Australia; \textsuperscript{2}Save Sight Institute, University of Sydney, Sydney, NSW, Australia; \textsuperscript{3}Ophthalmology Department, Addenbrooke’s Hospital, Cambridge, United Kingdom

Correspondence: Simon E Skalicky
Ophthalmology Department,
Addenbrooke’s Hospital, Box 41 Hills Rd,
Cambridge CB2 0QQ, United Kingdom
Tel +44 1223 256 691
Email seskalicky@gmail.com

Abstract: Recent advances in the understanding of dry eye disease (DED) have revealed previously unexplored targets for drug therapy. One of these drugs is diquafosol, a uridine nucleotide analog that is an agonist of the P2Y\textsubscript{2} receptor. Several randomized controlled trials have demonstrated that the application of topical diquafosol significantly improves objective markers of DED such as corneal and conjunctival fluorescein staining and, in some studies, tear film break-up time and Schirmer test scores. However, this has been accompanied by only partial improvement in patient symptoms. Although evidence from the literature is still relatively limited, early studies have suggested that diquafosol has a role in the management of DED. Additional studies would be helpful to delineate how different subgroups of DED respond to diquafosol. The therapeutic combination of diquafosol with other topical agents also warrants further investigation.

Keywords: dry eye disease, meibomian gland disease, aqueous tear deficiency, diquafosol, P2Y\textsubscript{2} agonists

Introduction

Dry eye disease (DED) is a complex clinical entity characterized by symptoms of discomfort and visual disturbance. It is associated with tear film instability, increased tear film osmolarity, and ocular surface inflammation.\textsuperscript{1} It has a high prevalence that, depending on the population studied, varies from 5% to 35%.\textsuperscript{2,3} DED commonly causes symptoms including foreign body sensation, dryness, irritation, itching, and light sensitivity.\textsuperscript{4} It impacts patients’ daily life and function. Utility assessment tools have shown that it influences quality of life as significantly as systemic morbidities such as angina and dialysis for chronic renal impairment.\textsuperscript{5,6}

Broadly, DED results from either decreased aqueous tear production (aqueous tear-deficient dry eye [ADDE]) or increased tear evaporation (evaporative dry eye [EDE]). Both conditions may occur together.\textsuperscript{1} The former may be associated with Sjögren’s syndrome or other systemic inflammatory conditions. The latter is predominantly associated with meibomian gland dysfunction.

With the rapid increase in information regarding the pathogenesis of DED, recent insights have provided a rational basis for the development of new pharmacologic agents. Among these is diquafosol tetrasodium (“diquafosol”), a uridine nucleotide analog that is an agonist of the P2Y\textsubscript{2} receptor. Diquafosol has been approved by regulatory bodies in Japan and Korea and is available under the trade name Diquas™ Ophthalmic Solution 3% (Santen Pharmaceutical Co, Ltd, Osaka, Japan).
This paper reviews the current evidence for the use of topical diquafosol for the treatment of DED. It will first provide a brief outline of the basic and clinical science underlying the use of this medication in dry eye treatment, followed by a review of published human clinical trials. A previous review has comprehensively evaluated the mechanism of diquafosol and human clinical data from Japanese studies; this present report includes clinical studies conducted elsewhere.

The P2Y\textsubscript{2} receptor and its role in ocular surface physiology

The P2Y\textsubscript{2} receptor belongs to the family of purinergic receptors,\textsuperscript{8} which have been classified into P1 receptors and P2 receptors on the basis of their native agonism by purine nucleosides and purine and pyrimidine nucleotides, respectively.\textsuperscript{9} P2 receptors are further distinguished physiologically into two types. P2X receptors are fast ion channels, whereas P2Y receptors are metabotropic guanosine triphosphate binding protein (G-protein) coupled receptors that mediate diverse biological effects through a cascade of downstream intracellular processes. The eight members of the P2Y receptor subfamily are divided into two groups on the basis of their G-protein coupling. Specifically, the P2Y\textsubscript{2} receptor couples to G\textsubscript{q} to activate phospholipase C-\beta.\textsuperscript{10}

Physiologically, P2Y receptors are activated by a range of purine and pyrimidine extracellular mononucleotides, such as adenosine-5'-triphosphate and uridine-5'-triphosphate,\textsuperscript{11} and dinucleotides, such as diadenosine polyphosphates.\textsuperscript{9,12} Although these mono- and dinucleotides are primarily located in the intracellular compartment, under conditions of cellular damage or death they can be released into the extracellular milieu and thus become available for binding with P2Y receptors. For this reason, it has been proposed that P2Y receptors and their native ligands mediate danger signaling.\textsuperscript{8} However, other mechanisms of release, including vesicular release and activation of adenosine-5'-triphosphate binding cassette transporters, have also been demonstrated.\textsuperscript{13} The physiologic roles of P2Y receptor signaling are diverse, including, most notably, platelet aggregation, but it has also been suggested to be involved in immunity, lipid metabolism, the gastrointestinal system, and bone activity, among other things.\textsuperscript{14}

Several studies have demonstrated the presence of P2X and P2Y receptors in ocular tissues, including the retina,\textsuperscript{15} ciliary body,\textsuperscript{16} and lens.\textsuperscript{17} These studies indicate that P2Y\textsubscript{2} receptors appear to be the main subtype of purinergic receptor located at the ocular surface.\textsuperscript{18} Some indirectly imply the presence of P2Y\textsubscript{2} receptors by demonstrating an in vitro selective response to exogenously applied P2Y\textsubscript{2} receptor agonists, involving an increase in intracellular calcium or stimulation of mucin secretion.\textsuperscript{9,19,20} Direct evidence for the presence of P2Y\textsubscript{2} receptors in ocular tissues includes the localization of P2Y\textsubscript{2} receptors in the conjunctival epithelial goblet and serous cells and meibomian gland acinus and ductal epithelial cells of the rhesus macaque by nons isotopic in situ hybridization.\textsuperscript{21}

Animal and human studies have demonstrated that native P2Y\textsubscript{2} agonists may be released at the ocular surface in response to trauma. In response to mechanical stress, cultured rabbit corneal epithelial cells have been shown to release nucleotides.\textsuperscript{22} Increasing blink rate and corneal mechanical stimulation in human subjects led to increased concentrations of diadenosine polyphosphates in tear secretions,\textsuperscript{23} as did 5 minutes of contact lens wear in a group of contact lens-naive subjects.\textsuperscript{24}

Animal studies have suggested that ocular surface application of P2Y\textsubscript{2} agonists promotes aqueous tear secretion. Diquafosol increased aqueous tear secretion in rats that had undergone surgical excision of their exorbital lacrimal glands.\textsuperscript{25} This was attributed to stimulation of net ion transport across the conjunctiva, as had been demonstrated in isolated rabbit conjunctiva.\textsuperscript{26} In vivo studies conducted on rabbits demonstrated that P2Y\textsubscript{2} agonists increased Schirmer values.\textsuperscript{27,28} P2Y\textsubscript{2} agonists increased mucin secretion in isolated rabbit and human conjunctiva.\textsuperscript{19} In vivo, P2Y\textsubscript{2} agonists also increased secretion of mucin in rabbits, as measured by an impression cytology technique.\textsuperscript{29}

P2Y\textsubscript{2} receptor agonists decreased fluorescein penetrance into rat cornea, as measured by a fluorophotometric method. This increase in corneal barrier function was felt to be secondary to increases in tear fluid and mucin, perhaps improving tight junctional resistance.\textsuperscript{25} Additionally, in vivo epithelial wound healing was accelerated by an unknown mechanism in the rabbit cornea by the application of the P2Y\textsubscript{2} agonists uridine-5'-triphosphate and diadenosine tetraphosphate, and inhibited by the application of P2Y\textsubscript{2} antagonists.\textsuperscript{30}

Through its intracellular calcium-raising effect, P2Y\textsubscript{2} receptor agonism is thought to open chloride channels in the apical membrane, leading to chloride flux and water transport.\textsuperscript{25,26} In goblet cells, the mechanism is less well defined, but presumably the increased intracellular calcium is coupled to the release of mucin from secretory granules.\textsuperscript{7}

Review of published clinical studies

Much of the clinical trial data relating to topical diquafosol for the treatment of DED has been presented in abstract
form at meetings and press releases and not reported in the literature. In the following review, only published clinical trial data have been included. The key clinical trials are summarized in Table 1.

**Methods**

A literature search was conducted using PubMed to identify all existing studies of diquafosol in patients with DED. The search was conducted without date limitations. Keywords used for the search included MeSH terms: dry eye syndromes and purinergic P2Y receptor agonists connected by “and” with the following MeSH and natural-language terms: diquafosol, aqueous deficiency, Sjögren’s syndrome, dry eye, and keratoconjunctivitis sicca. The abstracts for all studies meeting initial search criteria were reviewed; relevant studies were included. The reference list of all articles gathered was also reviewed for other potentially relevant articles.

**Safety**

No serious adverse events have been reported in the literature related to diquafosol. The initial Phase I trials investigating human safety and tolerability included two separate

**Table 1 Key clinical trials evaluating topical diquafosol therapy for dry eye disease**

<table>
<thead>
<tr>
<th>Study</th>
<th>Year of publication</th>
<th>Study design</th>
<th>Number of patients (n), study arms</th>
<th>Predominant type of dry eye studied</th>
<th>Duration (weeks)</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tauber et al34</td>
<td>2004</td>
<td>Randomized controlled trial</td>
<td>n=527 Three arms: 1) 1% diquafosol 2) 2% diquafosol 3) placebo</td>
<td>ADDE</td>
<td>24</td>
<td>Schirmer scores and corneal fluorescein staining significantly improved with both 1% and 2% diquafosol. Minor improvement in “clearing of foreign body sensation” on secondary (but not primary) analysis.</td>
</tr>
<tr>
<td>Matsumoto et al33</td>
<td>2012</td>
<td>Randomized controlled trial</td>
<td>n=286 Three arms: 1) 1% diquafosol 2) 3% diquafosol 3) placebo</td>
<td>ADDE</td>
<td>6</td>
<td>Corneal and conjunctival staining scores significantly improved with both 1% and 3% topical diquafosol with a dose-dependent effect. Eleven ocular symptoms were assessed. Only one (“dry eye sensation”) improved with diquafosol. Mean fluorescein staining scores and TBUT improved for both groups. No inferiority or superiority detected between groups. Rose bengal staining improved for both groups, with diquafosol superior to hyaluronate. Eleven ocular symptoms were assessed; superiority of diquafosol was demonstrated for one (“heaviness”).</td>
</tr>
<tr>
<td>Takamura et al35</td>
<td>2012</td>
<td>Randomized controlled trial</td>
<td>n=286 Two arms: 1) 3% diquafosol 2) 0.1% sodium hyaluronate</td>
<td>ADDE</td>
<td>4</td>
<td>Mean fluorescein staining scores and TBUT improved for both groups. No inferiority or superiority detected between groups. Rose bengal staining improved for both groups, with diquafosol superior to hyaluronate. Eleven ocular symptoms were assessed; superiority of diquafosol was demonstrated for one (“heaviness”).</td>
</tr>
<tr>
<td>Kamiya et al36</td>
<td>2012</td>
<td>Prospective, consecutive interventional case series</td>
<td>n=32 (64 eyes) For each patient: 1) one eye served as treatment group (sodium hyaluronate and diquafosol) 2) the other eye served as control (sodium hyaluronate)</td>
<td>ADDE insufficiently responsive to sodium hyaluronate monotherapy</td>
<td>4</td>
<td>Diquafosol eyes showed improvement in TBUT and corneal staining but not Schirmer test. Twelve symptoms were measured. Three (“dry eye sensation, pain, and foreign body sensation”) improved in diquafosol eyes.</td>
</tr>
</tbody>
</table>

**Abbreviations:** ADDE, aqueous tear-deficient dry eye; TBUT, tear film break-up time.
dose-escalation studies: one involving 50 healthy human subjects without any ocular disease,\textsuperscript{31} the other involving 60 subjects with mild to moderate dry eye.\textsuperscript{32} Adverse findings included mild eyelid erythema, mild conjunctival erythema, and transient mild conjunctival discharge. In subsequent Phase II and III clinical studies, no statistically significant difference was found in the adverse event rate between diquafosol and placebo after 6 weeks\textsuperscript{33} or 24 weeks\textsuperscript{34} of treatment, and between diquafosol and sodium hyaluronate after 4 weeks of treatment.\textsuperscript{35} Some of the common ocular adverse events reported were burning and stinging on instillation (7\%) with a 2\% diquafosol formulation, and irritation (6.3\%–12.5\%), eye pain (1.4\%–4.2\%), and conjunctival hyperemia (0.7\%–1.0\%) with a 3\% formulation.\textsuperscript{33,35} The 3\% diquafosol ophthalmic solutions used in some studies were preserved with benzalkonium chloride;\textsuperscript{35,36} many other studies did not explicitly state which preservative was used in the trial solutions.

**Efficacy**

**Aqueous tear-deficient dry eye**

There are three randomized controlled trials (RCTs) reported in the literature comparing diquafosol with either placebo or sodium hyaluronate in the treatment of DED predominantly related to ADDE. In addition, one study evaluated the role of diquafosol as an additive therapy to sodium hyaluronate, one assessed the impact of diquafosol on visual function, and another provided longer-term (6 months) data.

**Randomized controlled trials**

In one placebo-controlled RCT (n=527), Tauber et al\textsuperscript{34} demonstrated statistically significant improvement in some objective measures of dry eye, including fluorescein corneal staining score and Schirmer testing, but not in symptoms of DED. Inclusion criteria included 1) at least a 6-month history of DED, 2) specific dry eye symptoms, 3) a minimum corneal fluorescein staining score, and 4) an unanesthetized Schirmer score £7 mm. Contact lens wearers were excluded from this study, as were subjects with significant meibomian gland dysfunction or lid margin inflammation. Qualifying subjects were randomized to one of three groups: 1) placebo, 2) 1\% diquafosol, or 3) 2\% diquafosol.\textsuperscript{34} The frequency of drop application was four times daily. At week 6, both 1\% and 2\% diquafosol groups demonstrated statistically significant superiority over placebo in improvement of corneal staining score (1\% and 2\% groups) and conjunctival staining score (2\% group). Improvement in tear volume in both diquafosol groups, as measured by unanesthetized Schirmer testing, was statistically significant. The major subjective endpoint, improvement in clearing of foreign body sensation, did not reach statistical significance on primary analysis; however, a significant difference in favor of diquafosol was detected on secondary analysis of week 6, 8, and 10 data.

In a more recent placebo-controlled RCT (n=286), Matsumoto et al\textsuperscript{35} also demonstrated improvements in objective markers but little improvement in symptoms of DED. In this study, inclusion criteria were: 1) unanesthetized Schirmer score £5 mm and 2) any degree of corneal fluorescein staining after a 2-week washout period. Contact lens wearers were excluded. On the basis of the documented inclusion criteria and baseline patient characteristics revealing that 59 of the 286 (20.6\%) subjects had Sjögren’s syndrome, patients in this cohort were probably predominantly affected by ADDE, although no explicit exclusion criteria relating to meibomian gland dysfunction were documented. Subjects were randomized to receive 1) placebo, 2) 1\% diquafosol, or 3) 3\% diquafosol. Frequency of drop application was six times daily. The study duration of 6 weeks was preceded by a 2-week washout period. In this study, the primary endpoint was specified as fluorescein staining score at week 4 of treatment. Compared with placebo, both diquafosol groups demonstrated statistically significant dose-dependent improvements in fluorescein corneal staining scores at week 4 (1\% P=0.037; 3\% P=0.002). At week 6, the 3\% diquafosol group but not the 1\% group had significantly better fluorescein corneal staining compared with placebo (P=0.005). Compared with placebo, rose bengal corneal and conjunctival staining scores demonstrated significant improvement with both concentrations of diquafosol at the week 4 and week 6 time points. Although 3\% diquafosol improved tear film break-up time (TBUT), this was not statistically significant. Among eleven ocular symptoms assessed, only one of these (“dry eye sensation”) was significantly improved by diquafosol, with both treatment groups showing significant improvement over placebo at weeks 4 and 6.

Takamura et al\textsuperscript{35} compared 3\% diquafosol with 0.1\% sodium hyaluronate in an RCT (n=286) with two treatment arms in a 1:1 ratio. Patients qualified for inclusion based on: 1) unanesthetized Schirmer test £5 mm, 2) fluorescein staining scores ≥3 (out of nine points), and 3) rose bengal staining scores ≥3 (out of 15 points) following a 2-week run-in period in which no topical therapy except one drop of vehicle was applied six times daily. Again, no explicit exclusion criteria relating to meibomian gland dysfunction were documented. Treatment involved drops applied six times daily for 4 weeks. After 4 weeks, both groups showed significant
improvement in fluorescein staining (diquafosol = 2.12±0.14, sodium hyaluronate = 2.08±0.13) and TBUT compared with baseline. There was, however, no statistically significant inter-group difference. By contrast, the diquafosol group showed significantly improved rose bengal staining when compared with sodium hyaluronate at 4 weeks (P=0.010). Among eleven measured subjective parameters, only one (“heaviness”) was significantly improved in the diquafosol group compared with sodium hyaluronate group at week 4.

Additive effect of 3% diquafosol and 0.1% sodium hyaluronate
Kamiya et al analyzed the additive effect of 3% diquafosol and 0.1% sodium hyaluronate in 64 eyes of 32 consecutive patients with Sjögren’s syndrome or without Sjögren’s syndrome with ADDE who were insufficiently responsive to sodium hyaluronate monotherapy alone at a frequency of one drop six times a day. Each eye of the 32 patients was randomized to receive sodium hyaluronate (the “control group”), with the fellow eye receiving diquafosol (Diquas) and sodium hyaluronate (the “diquafosol group”). Statistically significant improvement in TBUT, fluorescein, and rose bengal staining scores was seen in the diquafosol group at 2 weeks and 4 weeks compared with baseline. In contrast, the control group did not achieve statistically significant improvements to these endpoints at either 2 weeks or 4 weeks. Neither group improved tear volume as measured by the Schirmer test. In this study, twelve subjective symptoms were measured using a visual analog scale graded between 0 and 100. Of the twelve subjective symptoms, only three (dry eye sensation, pain, and foreign body sensation) were improved significantly in the diquafosol group compared with baseline. The control group did not have any statistically significant change in subjective symptoms.

Functional evaluation
Another study (n=24) assessed the impact of diquafosol therapy on tear function and visual performance. Patients with short TBUTs (≤5s) were included; those with meibomian gland disease, blepharitis, lid malposition, nasolacrimal duct disease, or contact lens wear were excluded. Patients were divided into two groups based on the presence (n=11) or absence (n=13) of symptoms related to DED. Both groups were treated with diquafosol (Diquas) applied six times daily for 1 month. Higher order aberrations, as measured by wavefront aberrometry, were significantly reduced in the symptom-positive group only. Functional visual acuity, measured using a proprietary device, improved in both groups.

Preliminary long-term efficacy data
Preliminary long-term efficacy data for diquafosol in patients with ADDE have been published by Koh et al. Fifteen eyes of 15 subjects (Sjögren’s syndrome n=13, no Sjögren’s syndrome ADDE, n=2) were treated with 3% diquafosol (Diquas) for a period of 6 months at a frequency of six times daily. Twelve ocular symptoms were evaluated, with each symptom rated on a four-point scale at 1 month, 3 months, and 6 months compared with baseline. Significant improvement occurred at all time points. Mean corneal staining scores were significantly reduced at 1 month, 3 months, and 6 months compared with baseline. Conjunctival staining was significantly reduced at 3 months and 6 months. Both TBUT and tear meniscus height (measured by anterior-segment optical coherence tomography) were significantly increased at all time points compared with baseline. Despite the latter increase, Schirmer values were not significantly altered at any time point.

Evaporative dry eye
More recently, the role of diquafosol in treating EDE has been explored. Arita et al analyzed the effect of 3% diquafosol on 19 eyes of ten patients with obstructive meibomian gland dysfunction. Treatment was with four times daily 3% diquafosol (Diquas), and follow-up lasted at least 4 months (range 4–16 months). Improvements were seen in ocular symptoms, lid margin abnormalities, superficial punctate keratopathy, meibum grade, break-up time, and meniscus height in all 19 eyes. Statistical analysis was applied to quantitative noncontact meibography, which demonstrated an increase in meibomian gland coverage in all 19 eyelids from 36.9%±10.1% to 41.5%±9.2% after treatment (P<0.0001).

Discussion
Studies evaluating diquafosol therapy for ADDE demonstrated significant improvement in signs of DED but only partial improvement in symptoms.

In these studies, diquafosol consistently improved ocular surface staining. Two moderately large RCTs demonstrated that compared with placebo, diquafosol significantly reduced fluorescein corneal staining scores after a treatment period of between 4 weeks and 6 weeks using 1%, 2%, and 3% concentrations. This improvement in fluorescein corneal staining occurred in a dose-dependent manner. When diquafosol 3% was compared with sodium hyaluronate, after 4 weeks there appeared to be no statistically significant difference in fluorescein corneal staining. However, rose bengal staining was significantly improved with diquafosol when compared with sodium hyaluronate.
In comparison, improvements in TBUT were less consistent. Fluorescein TBUT data were not documented in the Tauber et al study. In the Matsumoto et al study, no significant difference from TBUT was demonstrated between 1% and 3% diquafosol and placebo at any time point. In the Takamura et al study, improvements from baseline in TBUT were documented in both the 3% diquafosol and 0.1% sodium hyaluronate groups, but there was no statistically significant difference between the two groups. Although a smaller study than the RCTs listed previously, Koh et al demonstrated improvements in TBUT at 1 month, 3 months, and 6 months, indicating, perhaps, a longer-term improvement in tear film stability.

In patients with DED calcitriol to sodium hyaluronate therapy alone, the addition of diquafosol improved fluorescein and rose bengal corneal staining scores as well as TBUT. This may suggest that certain subgroups of dry eye unresponsive to one therapy alone may respond with either alternative or additional treatment. Although an additional therapy may simply address different disease pathways simultaneously, these pathways may interact in a dynamic manner, and one therapy may potentiate or facilitate the effect of the other.

Although diquafosol appears to consistently improve ocular surface staining, improvements in DED subjective symptom scores have been disappointing. In the Tauber et al study, “clearing of foreign body sensation” at week 6 (defined as a primary endpoint) was not significantly different from placebo, although some improvement in symptoms was detected on secondary analysis. Matsumoto et al found that only one out of eleven subjective symptoms evaluated (“dry eye sensation”) improved significantly with diquafosol versus placebo. Similarly, Takamura et al found that only one of the eleven subjective symptoms evaluated (“heaviness”) improved significantly with diquafosol against sodium hyaluronate. Kamiya et al found significant improvements in three out of twelve subjective symptoms with the addition of diquafosol to sodium hyaluronate.

The discrepancy between improvement in signs and symptoms on treatment with topical diquafosol is relatively consistent throughout these clinical studies. However, previous studies have demonstrated that simply by improving the signs of DED, symptoms may not be alleviated, implying a poor correlation between the two. The reason for this is unclear and probably multifactorial. Due to its subjective nature, measuring patient symptoms is inherently difficult. In DED, challenges include a multifactorial etiology. It has been noted that both symptom frequency and intensity may differ among different etiologies of DED. The influence of psychological factors on the perception and expression of symptoms is also intertwined with the immeasurable effect of language and culture. These difficulties present significant ongoing challenges to clinical researchers and would be ameliorated by the introduction of a standardized method of assessing symptoms in all DED studies. Even in relation to the commonly used clinical tests for eliciting what are regarded as “objective” signs, there exists a poor relationship between tests intended to assess similar characteristics of the tears or ocular surface. This has been attributed to measurement error, as well as to the inherent variability of the tear and ocular surface status in an individual over time.

Although objective signs of amelioration with treatment are important for providing a solid rationale for introducing new therapies, the alleviation of sometimes distressing symptoms rightly also assumes primacy in DED management. This is reflected in the inclusion of ocular symptoms in all international definitions.

Studies utilizing various methods of corneal esthesiometry coupled with confocal microscopy to assess the change in corneal sensation and nerve morphology in patients with DED have demonstrated inconsistent findings. Some suggest that dry eyes are hyperesthetic, whereas others suggest that they are hypoesthetic. The reasons for these conflicting results are unresolved. Potentially, they are due to different subtypes, chronicities, and/or severities of DED being studied. Still, there is a consensus that corneal nerve function and additional larger long-term studies would be useful. It

All of the larger RCTs specified their primary endpoints at between 4 weeks and 6 weeks. Given the chronicity of DED, we postulate that even if short-term treatment with diquafosol restored corneal epithelial integrity (as measured by improved staining scores) and improved the thickness and stability of the overlying tear film, normalization of the inflammatory changes to the cornea and recovery of corneal nerve responsiveness may lag behind the surface improvements to some extent. In this regard, it is possible that improvements in patient symptoms may be borne out in longer-term studies. Koh et al demonstrated significant improvement to dry eye symptom scores over a 6-month treatment period. However, this was a small study (n=15), and additional larger long-term studies would be useful. It would be of great interest to study the effect of diquafosol treatment on the corneal nerves using confocal microscopy and esthesiometry, and relate this to changes in symptomatology over time. To the authors’ knowledge, no animal or
human study has examined the influence of P2Y<sub>2</sub> agonists on corneal nerve structure or function.

Diquafosol may have a role in treating EDE related to meibomian gland dysfunction. More studies with larger numbers are required to further evaluate its efficacy in improving signs and/or symptoms.

**Conclusion**

The published clinical trial data surrounding the use of diquafosol in the management of DED suggest that diquafosol consistently improves ocular surface staining and may improve tear film volume and stability. However, this is generally not accompanied with a major improvement in symptoms related to DED, although a few specific subjective symptoms improved across different studies.

Further studies may be useful to clarify its role in specific subgroups of DED, such as meibomian gland dysfunction, Sjögren’s syndrome, or DED recalcitrant to more traditional therapies. Longer-duration studies, as well as studies examining the effect of diquafosol on corneal sensation and nerve structure, and potential synergistic interplay between diquafosol and other therapeutic agents such as ocular lubricants, traditional topical immunomodulatory agents such as prednisolone and cyclosporine, and newer targeted molecular agents would also be of great interest.

Progress in the understanding of dry eye pathophysiology and advances in diagnostic methods will help us better understand the place of diquafosol in the overall picture of DED management, overcome the discrepancy between signs and symptoms, and find new markers to gauge efficacy in future clinical trials.

**Disclosure**

The authors have no conflicting relationship or financial interest in any aspect of this review.

**References**


